• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/20/25 4:16:03 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email
    8-K
    0001162194false00011621942025-06-182025-06-18

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): June 18, 2025

     

    Standard BioTools Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    (State or other jurisdiction of

    incorporation)

    001-34180

    (Commission File Number)

    77-0513190

    (I.R.S. Employer Identification Number)

    2 Tower Place, Suite 2000

    South San Francisco, California 94080

    (Address of principal executive offices and zip code)

    (650) 266-6000

    (Registrant's telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading Symbol

     

    Name of each exchange on which registered

    Common stock, $0.001 par value per share

     

    LAB

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Standard BioTools Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 18, 2025. The Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated 2011 Equity Incentive Plan, as amended (the “Plan”), increasing the number of shares of common stock reserved for issuance thereunder by 17,400,000 shares.

    The Plan is described in further detail in the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2025 (the “Proxy Statement”), which description is incorporated herein by reference. The complete text of the Plan is set forth in Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On April 25, 2025 (the “Record Date”), the Company had 379,822,268 shares of common stock issued and outstanding. A total of 326,864,517 votes, or approximately 86.06% of the total voting power of the shares of the Company’s capital stock issued and outstanding and entitled to vote at the Annual Meeting were represented in person or by proxy at the Annual Meeting. The following proposals are described in detail in the Proxy Statement. The final voting results for each of the matters submitted to a stockholder vote at the Annual Meeting are set forth below:

    1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, to hold office until the Company’s 2028 annual meeting of stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal:

    Nominee

     

    Votes For

     

    Votes Withheld

     

    Broker Non-Votes

    Kathy Hibbs

     

    235,917,851

     

    9,416,470

     

    81,530,196

    Frank Witney, Ph.D.

     

    240,269,516

     

    5,064,805

     

    81,530,196

     

    2. Advisory Vote on Approval of Executive Compensation. The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2024 was approved by the following votes:

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    241,143,534

     

    4,006,163

     

    184,624

     

    81,530,196

     

    3. Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 was approved by the following vote:

    Votes For

     

    Votes Against

     

    Abstentions

    322,915,281

     

    3,650,720

     

    298,516

     

    4. Approval of the Amendment to the Amended and Restated 2011 Equity Incentive Plan, as Amended. The proposal to approve the amendment to the Plan to increase the shares of common stock reserved thereunder by 17,400,000 shares was approved by the following votes:

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    223,394,563

     

    19,589,973

     

    2,349,785

     

    81,530,196

     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

     

    Description

    10.1+

     

    Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan, as Amended.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ________________________

    + Management compensation plan or arrangement.

     

     


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date:

     

    June 20, 2025

     

    STANDARD BIOTOOLS INC.

     

     

     

     

     

     

     

     

     

     

     

    By:

     

    /s/ Alex Kim

     

     

     

     

    Name:

     

    Alex Kim

     

     

     

     

    Title:

     

    Chief Financial Officer

     

     


    Get the next $LAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    SEC Filings

    See more
    • Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/23/25 9:11:17 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/20/25 4:16:03 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Standard BioTools Inc.

      SD - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/2/25 4:06:54 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      3/4/25 8:19:51 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/29/24 8:30:41 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $1,546,237 worth of shares (750,000 units at $2.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/26/24 8:10:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Standard BioTools downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

      2/27/25 6:22:46 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • TD Cowen initiated coverage on Standard BioTools with a new price target

      TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

      4/16/24 8:09:43 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies initiated coverage on Standard BioTools with a new price target

      Jefferies initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.25

      4/4/24 7:41:52 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

      Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milesto

      6/23/25 7:13:00 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

      Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business   Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina"), including Soma

      6/23/25 7:05:18 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking research, technological advancements and real-world applications of proteomics shaping the future of healthcare. The first session will be: Is More Really More? Evaluating the Case for High-Plex, High-Quality ProteomicsFriday, June 6, 2025 – 11:00 am ET Stephen Williams, MD, PhD, Chief Medical Officer at Standard BioTools wi

      5/30/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Troy was granted 94,592 shares, increasing direct ownership by 58% to 256,412 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 7:00:22 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Eloi Fenel M was granted 94,592 shares, increasing direct ownership by 67% to 236,183 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:52 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Carey Thomas D. was granted 94,592 shares, increasing direct ownership by 95% to 194,058 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:06 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Standard BioTools Appoints Alex Kim as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

      11/7/24 8:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

      5/15/23 7:30:14 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/14/24 3:32:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/12/24 6:01:47 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/4/24 1:59:57 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Financials

    Live finance-specific insights

    See more
    • Standard BioTools Reports First Quarter 2025 Financial Results

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

      5/6/25 4:01:00 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor R

      4/22/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies over 12 monthsStrong Balance sheet with $295 million in cash, cash equivalents, restricted cash, short-term investments and no material debt at year end 2024 expected to provide suffi

      2/26/25 4:01:00 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials